Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming ...

Hims & Hers Health Inc (HIMS) reports a 73% revenue surge and strategic acquisitions, while navigating challenges in cash ...

Aug 5 - Hims & Hers Health shares took a hit on Tuesday, dropping more than 10% in early trading. The telehealth company ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...

Despite short-term volatility and reliance on GLP-1 momentum, HIMS remains a long-term bullish play in the consumer digital ...

英为财情Investing.com - Hims Hers Health (NYSE: HIMS )星期一发布了第二季度的财报，数据显示，公司营收逊于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$0.17，总营收为$544.8M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$549.87M，每股收益为$0.15.

Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop. Find out why I maintain a 'Buy' rating ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Shares of Hims & Hers Health fell 13.5% in after-hours trading Monday after the telehealth company missed Wall Street’s ...

Hims & Hers Health (NYSE: HIMS), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling ...